Markets:

Overview

News

Currencies

International

Treasuries

Astellas Pharma Unsp/Adr (OP:ALPMY)

16.43 +0.34 (+2.14%)

Streaming Delayed Price Updated: 11:52 AM EST, Feb 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Astellas Pharma Unsp/Adr

< Previous 1 2 3 Next >

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that...

Via MarketMinute

Topics Intellectual Property

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗

November 12, 2025

Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.

Via Benzinga

Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients ↗

October 18, 2025

Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with bladder cancer.

Via Investor's Business Daily

Why Is Taysha Gene Therapies Stock Falling Friday? ↗

October 17, 2025

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.

Via Benzinga

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients ↗

August 12, 2025

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for cisplatin therapy.

Via Benzinga

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study ↗

July 10, 2025

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.

Via Benzinga

JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗

March 18, 2025

JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered.

Via Benzinga

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo ↗

February 11, 2025

Pfizer and Astellas' Padcev-Keytruda combo showed durable survival benefits in urothelial cancer, with a higher response rate and no new safety concerns.

Via Benzinga

Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise ↗

January 03, 2025

Elevation Oncology's ADCs target CLDN18.2 and HER3, with EO-3021 showing promising Phase 1 results and a $6.6 billion TAM in gastric and pancreatic cancers.

Via Benzinga

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact ↗

December 31, 2024

Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results.

Via Benzinga

1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst ↗

October 29, 2024

It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.

Via The Motley Fool

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗

October 16, 2024

William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales...

Via Benzinga

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Via Investor's Business Daily

Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data ↗

August 05, 2024

Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage...

Via Benzinga

MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗

February 22, 2024

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Via Talk Markets

Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal ↗

December 31, 2023

Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program....

Via Talk Markets

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗

December 29, 2023

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.

Via Benzinga

How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks ↗

October 22, 2023

The companies studied a combination of Keytruda and Padcev in bladder cancer patients.

Via Investor's Business Daily

Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study ↗

October 05, 2023

Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant...

Via Benzinga

Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years ↗

September 24, 2023

The multibillionaire's portfolio features some moneymaking ideas.

Via The Motley Fool

Why Is Seagen Stock Trading Higher Today? ↗

September 22, 2023

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC:

Via Benzinga

Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer ↗

September 22, 2023

The companies tested a key combination in patients with previously untreated bladder cancer.

Via Investor's Business Daily

What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? ↗

September 20, 2023

Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected

Via Benzinga

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

September 01, 2023

Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.

Via MarketBeat

Topics Economy

Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin ↗

August 07, 2023

The company is already under scrutiny after reports of side effects tied to Syfovre.

Via Investor's Business Daily

From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs ↗

July 07, 2023

Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as...

Via Benzinga

Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas ↗

June 17, 2023

Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates...

Via Talk Markets

Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles ↗

June 08, 2023

Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as

Via Benzinga

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.